Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

  1. Garassino, M.C.
  2. Gadgeel, S.
  3. Esteban, E.
  4. Felip, E.
  5. Speranza, G.
  6. Domine, M.
  7. Hochmair, M.J.
  8. Powell, S.
  9. Cheng, S.Y.-S.
  10. Bischoff, H.G.
  11. Peled, N.
  12. Reck, M.
  13. Hui, R.
  14. Garon, E.B.
  15. Boyer, M.
  16. Wei, Z.
  17. Burke, T.
  18. Pietanza, M.C.
  19. Rodríguez-Abreu, D.
Revue:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Année de publication: 2020

Volumen: 21

Número: 3

Pages: 387-397

Type: Article

DOI: 10.1016/S1470-2045(19)30801-0 GOOGLE SCHOLAR

Objectifs de Développement Durable